1. Generics Bulletin
  2. >>Legal & IP

Glenmark Shells Out A Further $25m To Resolve Civil Price-Fixing Charges

Firm Had Previously Agreed $30m Payout To Settle Criminal Charges Over Pravastatin Last Year

 
• By Dave Wallace

Glenmark Pharmaceuticals has agreed a $25m payout in the US to resolve its alleged liability under the False Claims Act linked to historical price-fixing allegations.

Glenmark logo on website under magnifying glass
Glenmark has agreed to pay $25m to resolve civil claims • Source: Shutterstock

Glenmark Pharmaceuticals has agreed to pay out a further $25m in the US, “to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug,” the US Department of Justice has announced.

The case is linked to historical allegations that the firm between 2013 and 2015 “paid and received compensation prohibited by the anti-kickback statute through arrangements on price, supply and allocation of customers with other pharmaceutical manufacturers for a generic drug manufactured

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

More from Generics Bulletin